Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmX TechnologiesASX:PHX 35 Debt-to-EBITDA is 1.10 as of Dec. 2025, which is 479% above its 10-year median of 0.19. GuruFocus rates ASX:PHX with a GF Score™ of 35/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 478 Healthcare Providers & Services companies, PharmX Technologies ranks better than 68.62% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PharmX Technologies's Debt-to-EBITDA or its related term are showing as below:
ASX:PHX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.1 Med: 0.19 Max: 1.07
Current: 1.07
During the past 13 years, the highest Debt-to-EBITDA Ratio of PharmX Technologies was 1.07. The lowest was 0.10. And the median was 0.19.
ASX:PHX's Debt-to-EBITDA is ranked better than 68.62% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.25
vs ASX:PHX: 1.07
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PharmX Technologies Debt-to-EBITDA Related Terms
PharmX Technologies Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for PharmX Technologies's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PHX vs VEEV, BTSG, HQY: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, PharmX Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmX Technologies Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PharmX Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
PharmX Technologies (ASX:PHX) has a Debt-to-EBITDA of 1.10 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PharmX Technologies. This is 479% above median its historical median of 0.19. Over the past decade, PharmX Technologies' Debt-to-EBITDA has ranged from 0.10 to 1.07. According to the industry distribution chart, PharmX Technologies ranks #150 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 31.4%.
Is PharmX Technologies' Debt-to-EBITDA too high?
PharmX Technologies' current Debt-to-EBITDA of 1.10 is 479% above median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 1.07. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.25. PharmX Technologies' value of 1.10 is 51.1% below this industry median. Based on the distribution chart, PharmX Technologies ranks #150 out of 478 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, PharmX Technologies has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, PharmX Technologies ranks #150 out of 478 companies for Debt-to-EBITDA. This puts PharmX Technologies in the upper half of its industry. The industry median Debt-to-EBITDA is 2.25. PharmX Technologies' value of 1.10 is 51.1% below this benchmark. Historically, PharmX Technologies' own Debt-to-EBITDA has ranged from 0.10 to 1.07 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 2.25, PharmX Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmX Technologies's current Debt-to-EBITDA of 1.10 is 51.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PharmX Technologies. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmX Technologies's current Debt-to-EBITDA is 1.10, which is 479% above median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.11 — trading 57.1% above its estimated fair value. The current Debt-to-EBITDA is 1.10, which is 479% above median its 10-year median of 0.19 and 51.1% below the Healthcare Providers & Services industry median of 2.25. PharmX Technologies' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Debt-to-EBITDA is 1.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmX Technologies (ASX:PHX) Overvalued in 2026?
Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued.
The current stock price of A$0.11 is trading 57.1% above its estimated GF Value™ of A$0.07.
GuruFocus considers PharmX Technologies to be Significantly Overvalued.
Key valuation signals for ASX:PHX:
Debt-to-EBITDA: 1.10 (479% above median its 10-year median of 0.19)
GF Value™: A$0.07 vs. price of A$0.11 (57.1% above fair value)
Industry Position: 51.1% below the Healthcare Providers & Services median (#150 of 478)
No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
35GF Score
Get the complete analysis for ASX:PHX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PHX has been successfully added to your 
